MRA: FDA accepts four new States
Recommendation

1/2 December 2026
How to implement EU-GMP Chapter 8
After a positive assessment, the US Food and Drug Administration (FDA) has approved four additional EU Member States to be fully covered by the current EU-FDA Mutual Recognition Agreement (MRA) of GMP inspections of human manufacturers.
In November 2018, the FDA confirmed the capability of Belgium, Denmark, Finland and Latvia. This means that the FDA can now rely on a total of 19 Member States to replace their own inspections - in addition to those mentioned these are:Croatia, France, Italy, Malta, Spain, Sweden, United Kingdom, Czech Republic, Greece, Austria, Hungary, Romania, Lithuania, Ireland and Portugal.
Related GMP News
09.11.2026FDA Updates how it Evaluates and Inspects Human Drug Facilities
09.11.2026FDA Warning Letter to US based Manufacturer: Sterile Manufacturing Failures
28.10.2026Inadequate Supplier Oversight and missing Tests: Lessons from an FDA Warning Letter
21.10.2026FDA Cites Serious CGMP Deficiencies at Stream2Sea
23.09.2026FDA Inspection as GMP Evidence? Swissmedic Opens Up a New Option
23.09.2026New: Coordination of GMP Inspections for Centrally Authorised Products


